| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 88381 |
DOTA-phenylalanine,DOTA-苯丙氨酸 |
143 |
wyh |
2024-12-03 |
| 88382 |
DOTA−Lysine−Biotin, DOTA -赖氨酸-生物素 |
140 |
wyh |
2024-12-03 |
| 88383 |
DOTA-GA,螯合剂DOTA肽缀合物 |
159 |
wyh |
2024-12-03 |
| 88384 |
DOTA共轭二膦酸盐,DOTA-HBP |
154 |
wyh |
2024-12-03 |
| 88385 |
DOTA-神经介素n ,DOTA-Neuromedin N |
134 |
wyh |
2024-12-03 |
| 88386 |
tris-烯丙基-DOTA , tris-allyl-DOTA |
132 |
wyh |
2024-12-03 |
| 88387 |
6-(苄氧羰基)氨基-3-(甲硫基)-1,2,4-四嗪;6-(benzyloxycarbonyl)amino-3-(methylthio)-1,2,4,5-tetrazine |
145 |
WYQ |
2024-12-03 |
| 88388 |
6-(乙酰氨基)-3-(甲硫基)-1,2,4-四嗪;6-(acetylamino)-3-(methylthio)-1,2,4,5-tetrazine |
163 |
WYQ |
2024-12-03 |
| 88389 |
cFLFLFK-PEG-DOTA ;细胞特异性肽-聚乙二醇-DOTA |
121 |
wyh |
2024-12-03 |
| 88390 |
6-[(叔丁氧基羰基)氨基]-3-(甲硫基)-1,2,4-四嗪;6-[(tert-butyloxycarbonyl)amino]-3-(methylthio)-1,2,4,5-tetrazine |
147 |
WYQ |
2024-12-03 |
| 88391 |
MMA-DOTA-Cys 61 ,DOTA-马来酰亚胺-半胱氨酸 |
164 |
wyh |
2024-12-03 |
| 88392 |
DOTA-BR96 ,DOTA标记BR96单克隆抗体 |
153 |
wyh |
2024-12-03 |
| 88393 |
DOTA-ggNle-cycmsh(hex),内酰胺桥环化肽偶联DOTA |
146 |
wyh |
2024-12-03 |
| 88394 |
DOTA-sCCK8[Phe2(p-CH2SO3H) ,大环DOTA偶联多肽 |
150 |
wyh |
2024-12-03 |
| 88395 |
3,6-双(1H-1,2,3,4-四唑-5-基氨基)-1,2,4,5-四嗪(BTATz);3,6-bis(1H-1,2,3,4-tetrazol-5-yl-amino)- 1,2,4,5-tetrazine |
147 |
WYQ |
2024-12-03 |
| 88396 |
3,3'-偶氮二(6-氨基-1,2,4,5-四嗪)(DAAT);3,3'-azobis(6-amino-1,2,4,5-tetrazine) |
309 |
WYQ |
2024-12-03 |
| 88397 |
c(DOTA-RGDf),大环螯合剂DOTA环化RGD肽序列 |
156 |
wyh |
2024-12-03 |
| 88398 |
3,6-双(吡啶-3-基)-1,2,4,5-四嗪(3,3'-吡喃);3,6-bis(pyridin-3-yl)-1,2,4,5-tetrazine (3,3'-pytz) |
154 |
WYQ |
2024-12-03 |
| 88399 |
3,6-双(2-甲氧基苯基)-1,2-二氢-1,2,4,5-四嗪(2-MDHT);3,6-bis(2-methoxyphenyl)-1,2-dihydro-1,2,4,5-tetrazine |
168 |
WYQ |
2024-12-03 |
| 88400 |
3,6-二甲基-1,2,4,5-四嗪;3,6-Dimethyl-1,2,4,5-tetrazine |
162 |
WYQ |
2024-12-03 |
| 88401 |
3,3'-偶氮(6-氨基-1,2,4,5-四嗪);3,3'-Azobis(6-amino-1,2,4,5-tetrazine)(DAAT) |
200 |
WYQ |
2024-12-03 |
| 88402 |
3,6-d二肼基-1,2,4,5-四嗪(DHT) |
151 |
WYQ |
2024-12-03 |
| 88403 |
DOTA-D-phe1-Tyr3-奥曲肽 ,Ga-68-DOTA-TATE |
129 |
wyh |
2024-12-03 |
| 88404 |
DOTA-cCCK,DOTA偶联胆囊收缩素(CCK)受体 |
226 |
wyh |
2024-12-03 |
| 88405 |
3,6-d氨基-1,2,4,5-四嗪(DATZ) |
157 |
WYQ |
2024-12-03 |
| 88406 |
3-d氨基-6-(3,5-二甲基乙基吡唑-1-基)-1,2,4,5-四嗪(ADMPT) |
193 |
WYQ |
2024-12-03 |
| 88407 |
[DOTA]LTT-SS28 ,生长抑素模拟物 |
196 |
wyh |
2024-12-03 |
| 88408 |
DOTA-minigastrin (CP04) , DOTA-小胃泌素(CP04) |
210 |
wyh |
2024-12-03 |
| 88409 |
DOTA-rhuEpo ; DOTA-酰肼偶联rhuEpo |
124 |
wyh |
2024-12-03 |
| 88410 |
1,2,4,5-四嗪 , 化学式:C2H2N4 |
240 |
WYQ |
2024-12-03 |
| 88411 |
DOTA-Benerotide ;靶向生长抑素受体 |
118 |
wyh |
2024-12-03 |
| 88412 |
1,2,4,5-Tetrazines by Palladium Catalysis(钯催化1,2,4,5-四嗪的合成) |
129 |
WYQ |
2024-12-03 |
| 88413 |
5-苯基-1,2,4-三嗪-3-胺为例,为C9H8N4 |
131 |
WYQ |
2024-12-03 |
| 88414 |
DOTA-PEG-LA-AuNP,DOTA-PEG-硫辛酸修饰纳米金纳米粒子 |
166 |
wyh |
2024-12-03 |
| 88415 |
3,6-二(吡啶-2-基)-1,2,4,5-四嗪(pytz) |
196 |
WYQ |
2024-12-03 |
| 88416 |
HYNIC-PEG11-Tz;联肼尼克酰胺-十一聚乙二醇-四嗪;HYNIC-PEG11-Tetrazine |
182 |
WYQ |
2024-12-03 |
| 88417 |
DOTA-NT肽偶联金纳米粒子 ,DOTA-NT-AuNPs |
137 |
wyh |
2024-12-03 |
| 88418 |
[Zr-89]Zr-DFO-PEG5-Tz;[Zr-89]Zr-DFO-PEG5-Tetrazine |
174 |
WYQ |
2024-12-03 |
| 88419 |
MeTz-NOTA-RGD;甲基四嗪-大环配体-多肽 |
186 |
WYQ |
2024-12-03 |
| 88420 |
DOTA-Tyr(3)-奥曲肽, DOTA-Tyr(3)-Octreotide |
126 |
wyh |
2024-12-03 |
| 88421 |
AgNPs–pytz(3,6-二(吡啶-2-基)-1,2,4,5-四嗪包覆的银纳米粒子) |
142 |
WYQ |
2024-12-03 |
| 88422 |
3,6-di(pyridin-2-yl)-1,2,4,5-s-tetrazine (pytz,3,6-二(吡啶-2-基)-1,4-二氢-1,2,4,5-四嗪) |
158 |
WYQ |
2024-12-03 |
| 88423 |
DOTA-叶酸偶联物,DOTA-Folate |
163 |
wyh |
2024-12-03 |
| 88424 |
CQDs-DOTA-Yb,镱-DOTA螯合物功能化碳量子点 |
144 |
wyh |
2024-12-03 |
| 88425 |
3,6-dihydrazino-s-tetrazine (DHT,3,6-二肼基-s-四嗪) |
154 |
WYQ |
2024-12-03 |